GeneBioTech Ltd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for GeneBioTech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	82.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

GeneBioTech Ltd's (KOSDAQ:086060) Soft Earnings Are Actually Better Than They Appear

Nov 21

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneBioTech Ltd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A086060 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	80,499	2,551	1,361	2,149	N/A
6/30/2024	80,028	2,426	1,546	2,069	N/A
3/31/2024	80,266	2,605	4,949	5,579	N/A
12/31/2023	79,477	2,591	6,602	7,369	N/A
9/30/2023	82,466	3,594	2,856	3,978	N/A
6/30/2023	84,897	2,600	2,040	3,073	N/A
3/31/2023	83,007	1,846	-951	410	N/A
12/31/2022	82,759	1,523	-4,853	-3,679	N/A
9/30/2022	78,270	316	-5,808	-4,599	N/A
6/30/2022	71,338	415	-4,488	-3,132	N/A
3/31/2022	68,923	338	-6,385	-5,093	N/A
12/31/2021	62,814	-484	-5,828	-2,713	N/A
9/30/2021	55,601	-486	-1,432	1,636	N/A
6/30/2021	56,974	189	-1,607	2,565	N/A
3/31/2021	58,137	103	-2,200	1,900	N/A
12/31/2020	59,119	1,029	-1,803	2,492	N/A
9/30/2020	62,309	905	-4,510	457	N/A
6/30/2020	59,849	493	-6,388	-2,115	N/A
3/31/2020	58,482	1,042	-4,847	-392	N/A
12/31/2019	58,245	847	-4,988	-2,682	N/A
9/30/2019	59,572	797	-3,671	-2,634	N/A
6/30/2019	59,637	1,386	-81	671	N/A
3/31/2019	60,224	2,378	1,290	1,769	N/A
12/31/2018	62,809	2,683	5,427	5,955	N/A
9/30/2018	60,961	1,702	3,082	4,013	N/A
6/30/2018	60,652	1,838	N/A	847	N/A
3/31/2018	58,785	2,309	N/A	4,593	N/A
12/31/2017	55,534	2,089	N/A	1,132	N/A
9/30/2017	56,241	3,934	N/A	3,453	N/A
6/30/2017	56,099	3,429	N/A	3,703	N/A
3/31/2017	55,262	2,402	N/A	3,136	N/A
12/31/2016	55,632	2,734	N/A	5,312	N/A
9/30/2016	54,845	2,163	N/A	4,537	N/A
6/30/2016	55,280	2,393	N/A	5,539	N/A
3/31/2016	54,410	2,235	N/A	2,549	N/A
12/31/2015	52,256	1,712	N/A	2,606	N/A
9/30/2015	51,990	1,635	N/A	1,901	N/A
6/30/2015	51,126	1,404	N/A	4,072	N/A
3/31/2015	50,972	1,312	N/A	3,463	N/A
12/31/2014	51,589	1,091	N/A	2,155	N/A
9/30/2014	50,192	1,068	N/A	3,128	N/A
6/30/2014	51,285	704	N/A	627	N/A
3/31/2014	52,612	151	N/A	904	N/A
12/31/2013	55,037	204	N/A	2,378	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A086060's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A086060's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A086060's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A086060's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A086060's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A086060's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 00:21
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GeneBioTech Co. ,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

GeneBioTech Ltd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

New major risk - Financial data availability

GeneBioTech Ltd's (KOSDAQ:086060) Soft Earnings Are Actually Better Than They Appear

Third quarter 2024 earnings released: EPS: ₩105 (vs ₩90.00 in 3Q 2023)

Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings

We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings

Full year 2023 earnings released: EPS: ₩301 (vs ₩177 in FY 2022)

Third quarter 2023 earnings released: EPS: ₩90.00 (vs ₩25.00 loss in 3Q 2022)

First quarter 2023 earnings released: EPS: ₩80.00 (vs ₩42.00 in 1Q 2022)

Full year 2022 earnings released: EPS: ₩177 (vs ₩56.00 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: ₩25.00 loss per share (vs ₩14.00 loss in 3Q 2021)

Less than half of directors are independent

Upcoming dividend of ₩30.00 per share

Third quarter 2021 earnings released: ₩14.00 loss per share (vs ₩65.00 profit in 3Q 2020)

Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend

Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?

Investor sentiment improved over the past week

New 90-day low: ₩5,110

Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden

Genebiotech Co., Ltd., Annual General Meeting, Mar 25, 2021

New 90-day low: ₩5,390

New 90-day low: ₩5,450

How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?

Upcoming Dividend of ₩30.00 Per Share

Is Genebiotech (KOSDAQ:086060) A Risky Investment?

Third quarter 2020 earnings released: EPS ₩65.00

New 90-day low: ₩5,250

New 90-day high - ₩6,690